Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.49 |
| ▸ | FYN | P06241 | 3/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | FES | P07332 | 2/20 | 0.49 |
| ▸ | ROS1 | P08922 | 2/20 | 0.49 |
| ▸ | FER | P16591 | 2/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345818 | 0.90 | OPRM1 (0.49) | FLT1FYNCHEK2CDK1FES | |
| SCHEMBL1347900 | 0.85 | CNR1 (0.55) | OPRM1OPRD1OPRK1HDAC8CFD | |
| SCHEMBL1345827 | 0.81 | CYP11B1 (0.55) | FLT1FYNCHEK2CDK1FES | |
| SCHEMBL1347785 | 0.81 | FYN (0.45) | FLT1FYNCHEK2CDK1FES | |
| SCHEMBL12650844 | 0.77 | HDAC1 (0.50) | FLT1FYNCHEK2CDK1FES | |
| SCHEMBL1345801 | 0.77 | HDAC6 (0.43) | FLT1FYNCHEK2CDK1FES | |
| SCHEMBL1788221 | 0.77 | OPRM1 (0.54) | CDC7AURKAROCK2PIM1CDK2 | |
| SCHEMBL1347867 | 0.77 | OPRM1 (0.62) | ROCK1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL3341545 | 0.77 | OPRM1 (0.62) | ROCK1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL13929187 | 0.76 | ERN1 (0.52) | FLT1FLT3CSF1RCNR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | claimed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| WO-2009030962-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | FLT1 2060/4885FYN 2403/4885CHEK2 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.